March 22, 2018 / 6:18 AM / 6 months ago

BRIEF-Pharma Mar: CHMP Confirms Negative Opinion On Aplidin In Multiple Myeloma

March 22 (Reuters) - PHARMA MAR SA:

* SAID ON WEDNESDAY CHMP CONFIRMS ITS PREVIOUS NEGATIVE OPINION RECOMMENDING NOT TO GRANT MARKETING AUTHORIZATION FOR APLIDIN IN MULTIPLE MYELOMA INDICATION

* REEXAMINATION PROCEDURE WAS REQUESTED BY CO IN JANUARY IN RELATION TO CHMP OPINION ISSUED IN DECEMBER

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below